Does ADALIMUMAB Cause Hyperparathyroidism secondary? 5 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Hyperparathyroidism secondary have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.0% of all adverse event reports for ADALIMUMAB.
5
Reports of Hyperparathyroidism secondary with ADALIMUMAB
0.0%
of all ADALIMUMAB reports
0
Deaths
3
Hospitalizations
How Dangerous Is Hyperparathyroidism secondary From ADALIMUMAB?
Of the 5 reports, 3 (60.0%) required hospitalization.
Is Hyperparathyroidism secondary Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does ADALIMUMAB Cause?
Drug ineffective (71,926)
Pain (37,514)
Arthralgia (35,592)
Rheumatoid arthritis (29,817)
Fatigue (29,420)
Injection site pain (28,679)
Headache (19,891)
Nausea (19,299)
Rash (18,690)
Pain in extremity (18,319)
What Other Drugs Cause Hyperparathyroidism secondary?
ESOMEPRAZOLE (1,357)
OMEPRAZOLE (1,274)
PANTOPRAZOLE (947)
LANSOPRAZOLE (888)
DEXLANSOPRAZOLE (382)
RABEPRAZOLE (108)
DENOSUMAB (60)
FUROSEMIDE (49)
OMEPRAZOLE\SODIUM BICARBONATE (48)
ESOMEPRAZOLE\NAPROXEN (47)
Which ADALIMUMAB Alternatives Have Lower Hyperparathyroidism secondary Risk?
ADALIMUMAB vs ADALIMUMAB-AACF
ADALIMUMAB vs ADALIMUMAB-AATY
ADALIMUMAB vs ADALIMUMAB-ADAZ
ADALIMUMAB vs ADALIMUMAB-ADBM
ADALIMUMAB vs ADALIMUMAB-AFZB